CN110627801A - HDAC inhibitor and application thereof - Google Patents
HDAC inhibitor and application thereof Download PDFInfo
- Publication number
- CN110627801A CN110627801A CN201910992789.6A CN201910992789A CN110627801A CN 110627801 A CN110627801 A CN 110627801A CN 201910992789 A CN201910992789 A CN 201910992789A CN 110627801 A CN110627801 A CN 110627801A
- Authority
- CN
- China
- Prior art keywords
- hdac
- inhibitor
- dioxa
- benzo
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims abstract description 35
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 38
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 38
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical class COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 5
- -1 hydroxy, cyano, carbamoyl Chemical group 0.000 claims description 35
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims description 22
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 35
- 238000003786 synthesis reaction Methods 0.000 description 35
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
- UEGLMSYFPSTPHJ-UHFFFAOYSA-N 6H-2-benzazepine-7-carboxamide Chemical compound C1=NC=CC=C2C1=CC=C(C2)C(=O)N UEGLMSYFPSTPHJ-UHFFFAOYSA-N 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 15
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 15
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 15
- 125000005605 benzo group Chemical group 0.000 description 15
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- HYHZGBOWRWIEGW-UHFFFAOYSA-N 5-methoxycarbonylthiophene-2-carboxylic acid Chemical group COC(=O)C1=CC=C(C(O)=O)S1 HYHZGBOWRWIEGW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XUUSYXJGMRQBKQ-UHFFFAOYSA-N 2h-2-benzazepine Chemical compound N1C=CC=C2C=CC=CC2=C1 XUUSYXJGMRQBKQ-UHFFFAOYSA-N 0.000 description 5
- HSSYVKMJJLDTKZ-UHFFFAOYSA-N 3-phenylphthalic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1C(O)=O HSSYVKMJJLDTKZ-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- SATDLKYRVXFXRE-UHFFFAOYSA-N methyl 4-(chloromethyl)benzoate Chemical compound COC(=O)C1=CC=C(CCl)C=C1 SATDLKYRVXFXRE-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HTBWBWWADZJXID-TXEJJXNPSA-N Wuweizisu C Chemical compound COC1=C2C=3C(OC)=C4OCOC4=CC=3C[C@H](C)[C@H](C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-TXEJJXNPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- DNMCSEZPFDMEHC-UHFFFAOYSA-N methyl 8-aminooctanoate;hydrochloride Chemical compound Cl.COC(=O)CCCCCCCN DNMCSEZPFDMEHC-UHFFFAOYSA-N 0.000 description 2
- IQLZWWDXNXZGPK-UHFFFAOYSA-N methylsulfonyloxymethyl methanesulfonate Chemical compound CS(=O)(=O)OCOS(C)(=O)=O IQLZWWDXNXZGPK-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- RVWMQSODNUSUBL-UHFFFAOYSA-N potassium;oxidoamine Chemical compound [K+].[O-]N RVWMQSODNUSUBL-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- TXZVCDJZNRCDKW-UHFFFAOYSA-N 2-(4-methoxycarbonylphenyl)acetic acid Chemical compound COC(=O)C1=CC=C(CC(O)=O)C=C1 TXZVCDJZNRCDKW-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- REIDAMBAPLIATC-UHFFFAOYSA-M 4-methoxycarbonylbenzoate Chemical compound COC(=O)C1=CC=C(C([O-])=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-M 0.000 description 1
- AETGYSUEDWYSME-UHFFFAOYSA-N 5-methoxycarbonylfuran-2-carboxylic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)O1 AETGYSUEDWYSME-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KOVPXZDUVJGGFU-UHFFFAOYSA-N 8-methoxy-8-oxooctanoic acid Chemical compound COC(=O)CCCCCCC(O)=O KOVPXZDUVJGGFU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- JBACYJRMCXLIQU-UHFFFAOYSA-N ethyl 5-(chloromethyl)furan-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(CCl)O1 JBACYJRMCXLIQU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- HTBWBWWADZJXID-UHFFFAOYSA-N gamma-schisandrin Natural products COC1=C2C=3C(OC)=C4OCOC4=CC=3CC(C)C(C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- PHRZTXWNFAEVIA-UHFFFAOYSA-N hydroxylamine;potassium Chemical compound [K].ON PHRZTXWNFAEVIA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- QHOVZTVDHVIBNK-UHFFFAOYSA-N methyl 2-(aminomethyl)pyrimidine-5-carboxylate hydrochloride Chemical compound Cl.COC(=O)c1cnc(CN)nc1 QHOVZTVDHVIBNK-UHFFFAOYSA-N 0.000 description 1
- GHQQSELFEUXDQA-UHFFFAOYSA-N methyl 2-(bromomethyl)pyrimidine-5-carboxylate Chemical compound COC(=O)C1=CN=C(CBr)N=C1 GHQQSELFEUXDQA-UHFFFAOYSA-N 0.000 description 1
- VHYFWKJZVCVUQH-UHFFFAOYSA-N methyl 4-(butylaminomethyl)benzoate Chemical compound CCCCNCC1=CC=C(C(=O)OC)C=C1 VHYFWKJZVCVUQH-UHFFFAOYSA-N 0.000 description 1
- YHSLJDKSLVUFDO-UHFFFAOYSA-N methyl 4-(methylaminomethyl)benzoate;hydrochloride Chemical compound Cl.CNCC1=CC=C(C(=O)OC)C=C1 YHSLJDKSLVUFDO-UHFFFAOYSA-N 0.000 description 1
- JUQDJGJWEGNMSX-UHFFFAOYSA-N methyl 5-(aminomethyl)thiophene-2-carboxylate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN)s1 JUQDJGJWEGNMSX-UHFFFAOYSA-N 0.000 description 1
- GFOPHLFSDVVYGB-UHFFFAOYSA-N methyl 5-(bromomethyl)thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)S1 GFOPHLFSDVVYGB-UHFFFAOYSA-N 0.000 description 1
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 108091073503 miR-548an stem-loop Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an HDAC inhibitor, which is a bifendate derivative shown in general formulas (I) - (IV), a pharmaceutically acceptable salt or a deuteron thereof, and a pharmaceutical composition containing the same, and application of the inhibitor in preparing anti-tumor, autoimmune disease, inflammation or Alzheimer disease drugs. The bifendate derivatives prepared by the invention have HDAC (histone deacetylase) inhibitory activity, and pharmacodynamic experiments show that the compounds can be used as medicaments for treating tumors, autoimmune diseases, inflammations or Alzheimer's disease.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to bifendate derivatives with HDAC (HDAC) inhibitory activity and a preparation method and application thereof.
Background
Histone Deacetylases (HDACs) play an important role in epigenetic regulation, and can regulate gene expression by catalyzing the deacetylation process of Histone or non-Histone. Of the four subcategories of HDACs, class I HDACs are closely related to tumorigenesis and development and are found in a wide variety of organs of the human body. The study demonstrated that HDAC1 subtype in HDACs class I is highly expressed in a variety of malignancies, such as endometrial, lung, prostate, breast, colon, Pancreatic, blood cancers, etc. (Zhu S, et al, Mir-548an, transcribed descending by HIF 1. alpha./HDAC 1, supra viral genetics of pathological Cancer by targeting expression. mol Cancer Ther,2016,15 (2209): 9-; Zhao R, et al, DNA damage-binding reactions HDAC1to expression Bcl-2transcription initiation man cell. mol Cancer, 2014,12(3): 370). High expression of HDAC1 can cause abnormal histone acetylation, and is closely related to tumor development and development, so the goal of treating tumor can be achieved by inhibiting HDAC1 (Stubbs, M.C, et al. selective Inhibition of HDAC1 and HDAC2 as aPotent Therapeutic Option for B-ALL. clin Cancer Res,2015,21(10): 2348-.
The HDAC6 subtype in class II HDACs has unique structural and substrate specificity, and its expression and functional changes are closely related to various diseases. The research shows that the abnormal expression of HDAC6 can promote the canceration of cells and the growth, proliferation and angiogenesis of tumor cells by regulating Ras, EGFR and other signal pathways; in addition, its high expression also enhances the metastatic and invasive properties of tumor cells (Lee YS, et al. the cytoplasmic deacylase HDAC6is required for clinical oncogenic clinical diagnosis. cancer Res,2008,68: 7561-. Meanwhile, HDAC6is also closely related to pathological processes of neurodegenerative diseases (such as Alzheimer disease), inflammation, autoimmune diseases, etc. (Selenica M L, et al, Histone deacetylase 6inhibition, memories and tau repair tools Resther,2014,6(1): 12; de Zoeten E F, et al, Histone deacetylase 6and Heat repair tools 90control the functions of Foxp3(+) T-regulation cells mol, 2011,31(10): 2066-2078; Rega N L et al, specificity HDAC 6inhibition, Y-transcription of acids and polypeptides, SLE W2016,162: N L, et al, specificity HDAC 6inhibition, SLE-transcription kinase, SLE 73, SLE 3, S5, S.
HDACs inhibitors which are now marketed mainly are broad-spectrum HDACs inhibitors, including vorinostat (SAHA), belinostat and panobinostat, but they have side effects such as nausea, vomiting, myelosuppression and prolongation of the QT interval, and their range of application is limited, so there is a strong need to find new HDAC inhibitors to improve the safety of this class of drugs (Balasuramanian S, et al, Isooform-specific histone deacetylase inhibitors: the next step? Cancer Lett,2009,280:211 @, 221.). subtype-selective HDAC inhibitors are currently the focus of research, in which HDAC6 selective inhibitors are of interest, but no HDAC drugs are marketed, only ACY-1215 are in clinical studies, besides direct intervention in the life activities of tumor cells, HDAC6 selective inhibitors may also down-regulate Programmed broad-spectrum Death ligands (Programmed Death-platelet-PD-1, thus exerting more selective action on HDAC inhibitors than HDAC inhibitors such as HDAC6, CD 6, HDAC inhibitors found to produce more selective effects than HDAC inhibitors for clinical therapy such as HDAC6, 16, 6, and multiple HDAC inhibitors.
Bifendate is a structural analogue of Chinese medicine monomer schisandrin and is clinically used as a liver protection medicine. In recent years, research and research have been conducted on the application of the compounds in the anti-tumor field. However, to date, no HDAC inhibitors based on the biphenyldicarboxylate parent nucleus have been reported.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a class of HDAC inhibitors and application thereof.
The technical scheme of the invention is as follows:
an HDAC inhibitor, wherein the inhibitor is a bifendate derivative shown as general formulas (I) - (IV) and a pharmaceutically acceptable salt or a deuteron thereof:
wherein, in the general formula (I) and (II), W is (CH)2)n1Or at least 1R1Substituted C6-14 aryl, C5-14 heteroaryl, C7-12 aralkyl, C6-12 heteroaralkyl;
in the general formula (III), X is at least 1R2Substituted C6-14 aryl, C5-14 heteroaryl, C7-12 aralkyl, C6-12 heteroaralkyl orWherein Y is at least 1R3Substituted C6-14 aryl, C5-14 heteroaryl;
in the general formula (IV), Z is at least substituted by 1R4Substituted C6-14 aryl, C5-14 heteroaryl;
n1=1-9;R1、R2、R3、R4each independently selected from hydrogen, halogen, hydroxy, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon; r5Is hydrogen, C1-6 alkyl orn2=1-4。
In a further embodiment, the bifendate derivatives represented by the general formulae (I) to (IV) are selected from the following compounds:
in a further embodiment, the HDAC inhibitor is a selective HDAC 6inhibitor, the selective HDAC 6inhibitor is a biphenyldicarboxylate derivative represented by the following general formulas (I) and (III) and a pharmaceutically acceptable salt or a deuteroxide thereof,
wherein in the general formula (I), W is at least 1R1Substituted C6-14 aryl, C5-14 heteroaryl; in the general formula (III), X is at least 1R2Substituted C6-14 aryl, C5-14 heteroaryl orAnd Y is at least 1R3Substituted C6-14 aryl, C5-14 heteroaryl; r1、R2、R3Each independently selected from hydrogen, halogen, hydroxy, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon; r5Is hydrogen, C1-6 alkyl orn2=1-4。
Further, the HDAC inhibitor is a selective HDAC1/2/3 inhibitor, the HDAC1/2/3 inhibitor is a biphenyldicarboxylate derivative represented by the general formula (IV) and a pharmaceutically acceptable salt or a deuteron thereof,
wherein,in the general formula (IV), Z is at least substituted by 1R4Substituted C6-14 aryl, C5-14 heteroaryl; r4Independently selected from hydrogen, halogen, hydroxyl, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon.
The present invention also provides an HDAC inhibitor composition comprising the HDAC inhibitor described above and at least one pharmaceutically acceptable carrier or excipient.
In a further aspect, the HDAC inhibitor composition further comprises at least one additional therapeutic agent.
The dosage form of the HDAC inhibitor composition is any clinically or pharmaceutically acceptable dosage form.
The invention also provides application of the HDAC inhibitor in preparing medicaments for resisting tumors, autoimmune diseases, inflammations or Alzheimer's diseases.
In addition, the invention also provides an application of the pharmaceutical composition or the HDAC inhibitor composition in preparing medicaments for resisting tumors, autoimmune diseases, inflammations or Alzheimer's diseases.
The dosage of the compound of the invention is 1mg-1000 mg/day, and the dosage can be deviated from the range according to the severity of the disease or the dosage form.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs.
Wherein "halogen" means fluorine, chlorine, bromine or iodine.
"C6-14 aryl" refers to an all carbon monocyclic or fused polycyclic group of 6 to 14 carbon atoms having a completely conjugated pi-electron system. Non-limiting examples thereof are: benzene ring, naphthalene ring, anthracene ring.
"C5-14 heteroaryl" refers to a non-all carbon monocyclic or fused polycyclic group of 5 to 14 ring atoms with a fully conjugated pi-electron system. Non-limiting examples thereof are: pyridine, imidazole, thiophene, furan, thiazole, purine, indole and azaindole.
"C6-12 arylheteroalkyl" means a group having an alkyl group attached to an heteroaryl group containing 6 to 12 carbon atoms;
"C7-12 aralkyl" means a group having an alkyl group attached to an aryl group having 7 to 12 carbon atoms;
"C1-6 alkyl" refers to an alkyl group of 1to 6 carbon atoms;
"C1-6 alkoxy" means that one hydrogen atom of an alkane of 1to 6 carbon atoms is replaced by an oxygen atom. Such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy, and the like;
"C2-6 unsaturated aliphatic hydrocarbon group" refers to a straight or branched chain alkenyl or alkynyl group having 2 to 6 carbon atoms and containing a double bond or a triple bond. Non-limiting examples of unsaturated aliphatic hydrocarbon groups are: vinyl, 1-propenyl, 2-propenyl, ethynyl and the like.
The compound or the pharmaceutically acceptable salt or the deuteron thereof has the same effect, wherein the pharmaceutically acceptable salt is the salt of the general formula (I), (II), (III) or (IV), and the pharmaceutically acceptable salt is hydrochloride, sulfate, phosphate, maleate, fumarate, citrate, methanesulfonate, tartrate, sodium salt or potassium salt.
The "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable carrier, and includes diluents, excipients (e.g., water, etc.), fillers (e.g., starch, etc.), binders (e.g., cellulose derivatives, gelatin, etc.), humectants (e.g., glycerin, etc.), disintegrants (e.g., agar-agar, calcium carbonate, etc.), absorption enhancers (e.g., quaternary ammonium compounds, etc.), surfactants (e.g., cetyl alcohol, etc.), adsorbent carriers (e.g., kaolin, bentonite, etc.), lubricants (e.g., talc, etc.), and flavoring agents, sweeteners, etc., as necessary.
The "pharmaceutically acceptable dosage form" is suitable for administration by any suitable route, such as the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. These formulations may be prepared by any method known in the art of pharmacy. For example, by admixing the active ingredient with a carrier or excipient.
The HDAC inhibitor is a bifendate derivative with HDAC inhibitory activity and a pharmaceutically acceptable salt or a deuterate thereof. The bifendate is a key intermediate for synthesizing Chinese medicine monomer schisandrin C, can be used as schisandrin C analogue structurally, is a common medicine for relieving transaminase rise caused by viral hepatitis and drug-induced liver injury in clinic, and has excellent safety. Recent studies have shown that biphenyldicarboxylate also has potential application value in tumor treatment, but studies on HDAC inhibitor discovery based on the basic skeleton of biphenyldicarboxylate have not been found yet.
Through multiple experiments, the bifendate derivatives prepared by the invention have HDAC (histone deacetylase) inhibition activity, and most compounds can inhibit HDAC1 or/and HDAC6 with high strength. Part of the compounds can inhibit HDAC1 at high intensity, show remarkable anti-tumor cell proliferation activity and have excellent selectivity on HDAC 1/2/3. Some other compounds show excellent HDAC6 selectivity while inhibiting HDAC6 at high intensity. Pharmacodynamic experiments show that the compound can be used as a therapeutic drug for tumors, autoimmune diseases, inflammations or Alzheimer's disease.
Detailed Description
Taking compound 1 (route I), compounds 2, 9, 12, 21 (route II) as examples, the compounds of the invention are prepared as follows:
alternatively, compounds 3-6 are prepared according to reference scheme I; compounds 7,8, 10, 11, 13-20 were prepared according to scheme II. It should be noted that the following specific examples are included for purposes of illustration and are not to be construed as limiting the scope of the invention. Further, it should be understood that various changes or modifications can be made by those skilled in the art after reading the contents of the present invention, and such equivalents also fall within the scope of the invention defined by the appended claims.
In route I: a is LiAlH4(lithium aluminum hydride), THF (tetrahydrofuran), 0 ℃;
b is MsCl (methanesulfonyl chloride), TEA (triethylamine), DCM (dichloromethane), rt (room temperature);
c is Methyl-8-aminoctanoate hydrochloride (8-aminocaprylic acid Methyl ester hydrochloride), TEA, CH3CN (acetonitrile), 40 ℃;
d is NH2OK (hydroxylamine potassium), CH3OH (methanol), rt.
In route II: a is Benzylamine (Benzylamine), TEA, CH3CN,40℃;
b is HCOONH4(ammonium formate), Pd/C (10%) (10% palladium on carbon), CH3OH,N2(nitrogen protection), 50 ℃;
c is methyl 4- (chloromethyl) benzoate (4-chloromethyl methyl benzoate), Cs2CO3(cesium carbonate), KI (potassium iodide), CH3CN,N2,80℃;
d is NH2OK,CH3OH,rt;
e is 5- (methoxycarbonyl) thiophene-2-carboxylic acid, EDC. HCl (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride), HOBT (1-hydroxybenzotriazole), DIPEA (N, N-diisopropylethylamine), DCM, rt;
f is methyl 4- (aminomethyl) benzoate hydrochloride, triphosgene, TEA, DCM, 0 deg.C-rt;
g is ethyl 2-chloropyrimidine-5-carboxylate (ethyl 2-chloropyrimidine-5-carboxylate), Cs2CO3KI (potassium iodide), CH3CN,N2,80℃。
Example 1:
synthesis of 8- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) -N-hydroxyoctanoylamide (1)
(1) Synthesis of (7,7' -dimethoxy- [4,4' -dibenzo [ d ] [1,3] dioxanone ] -5,5' -) dimethanol (23)
Biphenyl diester (10.0g,23.9mmol,1eq) was added to a round-bottomed flask, dissolved in anhydrous THF (150mL), and LiAlH was added in portions under ice bath4(2.72g,71.7mmol,3eq), after the addition was complete, the reaction was transferred to room temperature for 4 h. In ice bath, ice water was added to remove excess LiAlH4Suction filtration, DCM rinse, concentration of the filtrate, sequential use of saturated NaHCO3Washing the solution with water and saturated brine, anhydrous Na2SO4Drying, filtering, and concentrating the filtrate under reduced pressure to obtain white solid 8.33 g.
(2) Synthesis of (7,7' -dimethoxy- [4,4' -dibenzo [ d ] [1,3] dioxanone ] -5,5' -) bis (methylene) dimesylate (24)
Intermediate 23(5.50g,15.2mmol,1eq) was added to a round bottom flask, dissolved in DCM (50mL), and TEA (6.33mL,45.5mmol,3eq) and MsCl (3.84mL,45.5mmol,3eq) were added sequentially under ice bath and transferred to room temperature for 8 h. The system is sequentially saturated with NaHCO3Washing the solution with water and saturated brine, anhydrous Na2SO4Drying, filtering and concentrating the filtrate under reduced pressure to obtain 7.57g of yellow oily substance which is directly used for the next reaction.
(3) Synthesis of methyl 8- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) octanoate (25)
A round bottom flask was charged with intermediate 24(200mg,0.386mmol,1eq), methyl 8-aminocaprylate hydrochloride (323mg,1.54mmol,4eq), TEA (0.322mL,2.31mmol,6eq), and CH in that order3CN (3mL), reacted at 40 ℃ for 8 h. Rotate to remove CH3CN, in turn with saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4Drying, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain light yellow solid 163 mg.
(4) Synthesis of 8- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) -N-hydroxyoctanoyl amide (1)
NH2Preparation of OK methanol solution: KOH (9.70g,173mmol,1.5eq) was weighed into a round bottom flask and dissolved in methanol (24 mL); weighing NH2OH & HCl (8.00g,115mmol,1eq) was placed in a three-necked flask and dissolved in methanol (40 mL); under ice bath, KOH methanol solution was added dropwise to NH2OH HCl in methanol solution, N2Reacting for 1h under protection, and performing suction filtration to obtain filtrate for later use.
In a round bottom flask, intermediate 25(130mg, 0.293mmol,1eq), NH were added sequentially2OK methanol solution (4mL) was reacted at room temperature for 4 h. Adjusting pH to 7 with 1N HCl solution, separating out solid, vacuum filtering, washing filter cake with water, drying, and performing silica gel column chromatography to obtain yellow solid 80 mg;1H NMR(400MHz,DMSO-d6):δ10.38(s,1H),8.67(s,1H),6.98(s,2H),6.12(s,2H),6.07(s,2H),4.41-4.28(m,1H),4.14-4.00(m,1H),3.90(s,6H),3.78-3.66(m,1H),3.22-2.85(m,3H),1.96(t,J=7.2Hz,2H),1.86-1.76(m,1H),1.75-1.65(m,1H),1.51(t,J=6.8Hz,2H),1.37-1.27(m,6H);ESI-MS:501.19[M+H]+。
example 2:
synthesis of 4- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxybenzamide (2)
(1) Synthesis of 7-benzyl-4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine (25)
A round bottom flask was charged with intermediate 24(7.57g,14.6mmol,1eq), CH in that order3CN (50mL), benzylamine (6.38mL,58.4mmol,4eq) and TEA (8.12mL,58.4mmol,4eq) were reacted at 40 ℃ for 8 h. Rotate to remove CH3CN, in turn with saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4Drying, filtering, decompressing and concentrating the filtrate, and recrystallizing with ethyl acetate to obtain 5.01g of white solid.
(2) Synthesis of 4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine (26)
A round bottom flask was charged with intermediate 25(5.00g,11.5mmol,1eq), HCOONH in that order4(4.00g,63.4mmol,5.5eq), 10% Pd/C (1.10g), methanol (50mL), N2Protecting, and stirring and reacting for 10h at 50 ℃. Filtering to remove Pd/C, rinsing with methanol, concentrating the filtrate under reduced pressure, sequentially adding saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4Drying, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain light yellow solid 2.09 g.
(3) Synthesis of methyl 4- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) benzoate (27)
The intermediate 26(150mg,0.437mmol,1eq), methyl 4-chloromethylbenzoate (96.8mg,0.524mmol,1.2eq), and Cs were added to a round-bottomed flask in this order2CO3(185mg,0.524mmol,1.2eq), KI (87mg,0.524mmol,1.2eq) and anhydrous CH3CN(2mL),N2Protecting, and reacting at 80 ℃ for 9 h. Rotary wrenchRemoving CH3CN, in turn with saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4Drying, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain yellow solid 206 mg.
(4) Synthesis of 4- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxybenzamide (2)
Compound 2 was prepared according to example 1, step (4).
1H NMR(400MHz,DMSO-d6):δ11.20(s,1H),9.03(s,1H),7.76(d,J=8.0Hz,2H),7.48(d,J=8.0Hz,2H),6.65(s,2H),6.05(s,2H),6.00(s,2H),3.88(s,6H),3.72(d,J=13.6Hz,1H),3.54(d,J=13.6Hz,1H),3.44(d,J=12.8Hz,2H),3.03(d,J=12.4Hz,2H);ESI-MS:493.24[M+H]+。
Example 3:
synthesis of 5- (4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carbonyl) -N-hydroxythiophene-2-carboxamide (9)
(1) Synthesis of methyl 5- (4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carbonyl) thiophene-2-carboxylate (28)
5-methoxycarbonylthiophene-2-carboxylic acid (89.5mg,0.481mmol,1.1eq), EDC & HCl (92.1mg,0.481mmol,1.1eq), HOBt (65.4mg,0.481mmol,1.1eq), DIPEA (217. mu.L, 1.31mmol,3eq) and DCM (2mL) were added in this order to a round-bottomed flask and stirred at room temperature for 1 h. Intermediate 26(150mg,0.437mmol,1eq) was added and the reaction was continued at room temperature for 4 h. Sequentially with saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4DryingFiltering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain yellow solid 208 mg.
(2) Synthesis of 5- (4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carbonyl) -N-hydroxythiophene-2-carboxamide (9)
Compound 9 was prepared according to step (4) in example 1.
1H NMR(400MHz,DMSO-d6):δ11.41(s,1H),9.29(s,1H),7.59(d,2.8Hz,1H),7.53(d,4.0Hz,1H),6.88(s,1H),6.75(s,1H),6.09(s,2H),6.04(s,2H),5.17-4.71(m,2H),4.27-4.01(m,1H),3.85(s,6H),3.65-3.49(m,1H);ESI-MS:513.08[M+H]+。
Example 4:
synthesis of N- (4- (hydroxycarbamoyl) benzyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (12)
(1) Synthesis of methyl 4- ((4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamido) methyl) benzoate (29)
Methyl 4-aminomethylbenzoate hydrochloride (150mg,0.744mmol,1eq) was added to a round-bottom flask, dissolved in a DCM/saturated sodium bicarbonate solution system (V: V ═ 1:1,4mL), triphosgene (73.6mg,0.248mmol,0.33eq) was added under ice-bath, and the reaction was stirred for 0.5 h. Intermediate 26(255mg,0.744mmol,1eq) and TEA (310. mu.L, 2.23mmol,3eq) were added and transferred to room temperature for 6 h. Sequentially with saturated NaHCO3The solution, water and saturated brine are washed, DCM is used for extraction, and anhydrous Na is added2SO4Drying, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain 145mg of yellow solid.
(2) Synthesis of N- (4- (hydroxycarbamoyl) benzyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (12)
Compound 12 was prepared according to step (4) in example 1.
1H NMR(400MHz,DMSO-d6):δ11.18(s,1H),9.01(s,1H),7.70(d,8.0Hz,2H),7.35(d,8.0Hz,2H),7.22(t,4.8Hz,1H),6.78(s,2H),6.07(s,2H),6.02(s,2H),4.74(d,J=13.2Hz,2H),4.36(dd,J=15.2,4.8Hz,1H),4.28(dd,J=15.2,4.8Hz,1H),3.87(s,6H),3.47(d,J=13.2Hz,2H);ESI-MS:536.12[M+H]+。
Example 5:
synthesis of 2- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) -N-hydroxypyrimidine-5-carboxamide (21)
(1) Synthesis of ethyl 2- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) pyrimidine-5-carboxylate (30)
Intermediate 30 was prepared according to example 2, step (3), substituting only methyl 4-chloromethylbenzoate with ethyl 2-chloro-5-pyrimidinecarboxylate.
(2) Synthesis of 2- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepin-7-yl) -N-hydroxypyrimidine-5-carboxamide (21)
Compound 21 was prepared according to step (4) of reference example 1.
1H NMR(400MHz,DMSO)δ11.13(s,1H),9.04(s,1H),8.76(s,2H),6.81(s,2H),6.08(s,2H),6.03(s,2H),5.43(d,J=13.6Hz,2H),3.85(s,6H),3.67(d,J=13.6Hz,2H);ESI-MS:481.10[M+H]+。
Example 6:
synthesis of 5- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxythiophene-2-carboxamide (3)
Compound 3 was prepared according to example 5, replacing only ethyl 2-chloro-5-pyrimidinecarboxylate with methyl 5- (bromomethyl) thiophene-2-carboxylate.
1H NMR(400MHz,DMSO-d6):δ11.15(s,1H),9.09(s,1H),7.50(s,1H),7.08(s,1H),6.67(s,2H),6.05(s,2H),6.01(s,2H),4.12-4.01(m,1H),3.89(s,6H),3.70(d,12.4Hz,1H),3.54(d,11.6Hz,2H),3.04(d,11.2Hz,2H);ESI-MS:498.94[M+H]+。
Example 7:
synthesis of 5- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxyfuran-2-carboxamide (4)
Compound 4 was prepared according to example 5, substituting only ethyl 2-chloro-5-pyrimidinecarboxylate with ethyl 5- (chloromethyl) furan-2-carboxylate.
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.04(s,1H),7.02(d,2.8Hz,1H),6.72(s,2H),6.55(d,J=3.2Hz,1H),6.04(s,2H),6.00(s,2H),3.88(s,6H),3.69(d,J=14.0Hz,1H),3.52(d,J=14.4Hz,1H),3.47(d,J=12.8Hz,2H),3.04(d,J=12.4Hz,2H);ESI-HRMS:483.1338[M+H]+。
Example 8:
synthesis of 2- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxypyrimidine-5-carboxamide (5)
Compound 5 was prepared according to example 5, substituting only ethyl 2-chloro-5-pyrimidinecarboxylate with methyl 2- (bromomethyl) pyrimidine-5-carboxylate. ESI-MS 495.15[ M + H ]]+。
Example 9:
synthesis of 6- ((4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) methyl) -N-hydroxynicotinamide (6)
Compound 6 was prepared according to example 5, substituting only ethyl 2-chloro-5-pyrimidinecarboxylate with methyl 2- (bromomethyl) pyridine-5-carboxylate.
1H NMR(400MHz,DMSO-d6):δ11.35(s,1H),9.16(s,1H),8.87(d,J=1.6Hz,1H),8.13(dd,J=8.0,1.6Hz,1H),7.64(d,J=8.0Hz,1H),6.71(s,2H),6.05(s,2H),6.01(s,2H),3.93-3.83(m,7H),3.65(d,J=14.0Hz,1H),3.48(d,J=12.4Hz,2H),3.09(d,J=12.4Hz,2H);ESI-HRMS:494.1547[M+H]+。
Example 10:
synthesis of 8- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) -N-hydroxy-8-oxooctanoyl amide (7)
Compound 7 was prepared according to example 3, substituting only 5-methoxycarbonylthiophene-2-carboxylic acid with monomethyl suberate.
1H NMR(400MHz,DMSO-d6):δ10.33(s,1H),8.66(s,1H),6.97(s,1H),6.75(s,1H),6.06(s,2H),6.01(s,2H),5.11(d,J=13.6Hz,1H),4.65(d,J=13.2Hz,1H),3.88(s,3H),3.86(s,3H),3.72(d,J=13.2Hz,1H),3.27(d,J=13.6Hz,1H),2.58-2.54(m,1H),2.44-2.37(m,1H),1.94(t,J=7.2Hz,2H),1.56-1.46(m,4H),1.35-1.27(m,4H);ESI-MS:515.09[M+H]+。
Example 11:
synthesis of 4- (4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carbonyl) -N-hydroxybenzamide (8)
Compound 8 was prepared according to example 3, substituting only 5-methoxycarbonylthiophene-2-carboxylic acid with monomethyl terephthalate.
1H NMR(400MHz,DMSO-d6):δ11.34(s,1H),9.16(s,1H),7.87(d,J=8.0Hz,2H),7.56(d,J=8.0Hz,2H),6.95(s,1H),6.41(s,1H),6.08(s,2H),6.03(s,2H)5.11(d,J=13.6Hz,1H),4.27(d,J=13.2Hz,1H),3.98-3.85(m,4H),3.81(s,3H),3.58(d,J=13.6Hz,1H);ESI-MS:506.99[M+H]+。
Example 12:
synthesis of 5- (4, 10-dimethoxy-7, 8-dihydro-6H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carbonyl) -N-hydroxyfuran-2-carboxamide (10)
Compound 10 was prepared according to example 3, substituting only 5-methoxycarbonylthiophene-2-carboxylic acid with 5-methoxycarbonylfuran-2-carboxylic acid. ESI-MS 497.11[ M + H ]]+。
Example 13:
synthesis of 4- (2- (4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-) -2-oxoethyl) -N-hydroxybenzamide (11)
Compound 11 was prepared according to example 3, substituting only 5-methoxycarbonylthiophene-2-carboxylic acid with 4- (methoxycarbonyl) phenylacetic acid. ESI-MS 521.16[ M + H ]]+。
Example 14:
synthesis of N- ((5- (hydroxycarbamoyl) pyrimidin-2-) methyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (13)
Compound 13 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl 2-aminomethylpyrimidine-5-carboxylate hydrochloride. ESI-MS 538.16[ M + H ]]+。
Example 15:
synthesis of N- ((5- (hydroxycarbamoyl) thiophen-2-) methyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (14)
Compound 14 was prepared according to example 4, substituting only 4-aminomethylbenzoic acid methyl ester hydrochloride with 5-aminomethylthiophene-2-carboxylic acid methyl ester hydrochloride.
1H NMR(400MHz,DMSO-d6):δ10.35(s,1H),9.10(s,0.7H),8.55(s,0.3H),7.51-7.40(m,1H),7.34(t,5.2Hz,1H),6.95(d,J=2.8Hz,1H),6.78(s,2H),6.07(s,2H),6.02(s,2H),4.71(d,J=13.2Hz,2H),4.48(dd,J=15.6,5.2Hz,3H),4.37(dd,J=15.6,5.2Hz,3H),3.88(s,6H),3.46(d,J=13.2Hz,2H);ESI-HRMS:542.1226[M+H]+。
Example 16:
(E) synthesis of (E) -N- (4- (3- (hydroxyamino) -3-oxoprop-1-en-1-) benzyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (15)
Compound 15 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl (E) -4-aminomethylbenzoate hydrochloride.
1H NMR(400MHz,DMSO-d6):δ10.74(s,1H),9.03(s,1H),7.51(d,J=7.6Hz,2H),7.44(d,J=15.6Hz,1H),7.33(d,J=8.0Hz,2H),7.18(t,J=5.2Hz,1H),6.78(s,2H),6.44(d,J=15.6Hz,1H),6.07(s,2H),6.02(s,2H),4.74(d,J=13.2Hz,2H),4.36(dd,J=15.6,5.2Hz,1H),4.25(dd,J=15.6,5.2Hz,1H),3.87(s,6H),3.47(d,J=13.2Hz,2H);ESI-HRMS:562.1818[M+H]+。
Example 17:
synthesis of N- (4- (hydroxycarbamoyl) benzyl) -4, 10-dimethoxy-N-methyl-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (16)
Compound 16 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl 4- ((methylamino) methyl) benzoate hydrochloride.
1H NMR(400MHz,DMSO-d6):δ11.20(s,1H),9.02(s,1H),7.76(d,J=7.6Hz,2H),7.42(d,J=7.2Hz,2H),6.75(s,2H),6.06(s,2H),6.01(s,2H),4.53(d,J=15.2Hz,1H),4.28(d,J=10.8Hz,1H),4.23(d,J=12.8Hz,2H),3.87(s,6H),3.61(d,J=12.8Hz,2H),2.79(s,3H);ESI-MS:550.18[M+H]+。
Example 18:
synthesis of N- (4- (hydroxycarbamoyl) benzyl) -N-ethyl-4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (17)
Compound 17 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl 4- ((ethylamino) methyl) benzoate hydrochloride.1H NMR(400MHz,DMSO-d6):δ11.20(s,1H),9.02(s,1H),7.75(d,J=8.0Hz,2H),7.43(d,J=7.6Hz,2H),6.73(s,2H),6.07(s,2H),6.01(s,2H),4.56(d,J=15.6Hz,1H),4.32-4.17(m,3H),3.88(s,6H),3.62(d,J=12.8Hz,2H),3.26–3.19(m,1H),3.16–3.04(m,1H),1.14(t,J=6.4Hz,3H);ESI-HRMS:564.1976[M+H]+。
Example 19:
synthesis of N- (4- (hydroxycarbamoyl) benzyl) -N-N-butyl-4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (18)
Compound 18 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl 4- ((butylamino) methyl) benzoate hydrochloride.
1H NMR(400MHz,DMSO-d6):δ11.21(s,1H),9.04(s,1H),7.74(d,J=8.0Hz,2H),7.41(d,J=8.0Hz,2H),6.69(s,2H),6.07(s,2H),6.01(s,2H),4.59(d,J=15.6Hz,1H),4.24(d,J=13.2Hz,2H),4.17(d,J=16.0Hz,1H),3.87(s,6H),3.62(d,J=13.2Hz,2H),3.28-3.20(m,1H),3.01-2.91(m,1H),1.61-1.51(m,2H),1.32-1.27(m,2H),0.87(t,J=10.0Hz,3H);ESI-MS:592.22[M+H]+。
Example 20:
synthesis of N- (4- (hydroxycarbamoyl) benzyl) -N- (3-hydroxypropyl) -4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (19)
Compound 19 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl 4- (((3-hydroxypropyl) amino) methyl) benzoate hydrochloride.
1H NMR(400MHz,DMSO-d6):δ11.20(s,1H),9.03(s,1H),7.74(d,J=8.4Hz,2H),7.39(d,J=8.4Hz,2H),6.73(s,2H),6.06(s,2H),6.01(s,2H),4.58(d,J=15.6Hz,1H),4.49(t,J=5.2Hz,1H),4.29-4.19(m,3H),3.87(s,6H),3.61(d,J=13.2Hz,2H),3.45-3.42(m,2H),3.30-3.23(m,1H),3.10-3.01(m,1H),1.79-1.70(m,2H);ESI-HRMS:594.2084[M+H]+。
Example 21:
(E) synthesis of (E) -N- (4- (3- (hydroxyamino) -3-oxoprop-1-en-1-yl) benzyl) -N-methyl-4, 10-dimethoxy-6, 8-dihydro-7H- [1,3] dioxa [4',5':3,4] benzo [1,2-c ] [1,3] dioxa [4',5':5,6] benzo [1,2-e ] azepine-7-carboxamide (20)
Compound 20 was prepared according to example 4, substituting only methyl 4-aminomethylbenzoate hydrochloride with methyl (E) -3- (4- ((methylamino) methyl) phenyl) acrylate hydrochloride. ESI-HRMS 576.1980[ M + H ]]+。
Example 22: HDAC1 enzyme inhibitory Activity of Compounds of the invention
In this example, a broad-spectrum HDACs inhibitor SAHA from the market was used as a positive control, and fluorescence-based HDAC Activity Assay was used to evaluate the HDAC1 enzyme inhibitory Activity of the compound of the present invention and SAHA. Other compounds of the present invention have similar beneficial effects to those listed below, but this should not be understood as the only beneficial effects of the compounds of the present invention.
The HDAC1 enzyme inhibitory activity was tested by the following steps: preparing a DMSO solution of a compound to be detected, and sequentially preparing a buffer solution, an enzyme solution and a corresponding Substrate/Trypsin mixed solution according to the kit instructions; mixing the compound solution with gradient concentration, enzyme solution and hydrate/TrypsinAdding the solution into 384-well plates respectively to prepare a catalytic reaction system (no compound control and no enzyme control wells); after incubation for a certain time at room temperature, continuously reading a fluorescence signal value by using a Synergy enzyme-labeling instrument, selecting a linear reaction section to obtain a slope (slope), and further calculating the inhibition rate and IC (integrated circuit) under each concentration50Obtained by fitting GraphPad Prism 5 software.
Table 1: inhibitory Activity of Compounds on HDAC1 enzymes
In the above table: "+ ++" represents 0-20 nM; "+ + + +" represents 20-100 nM.
As can be seen from the data in table 1, all of the compounds listed exhibited significant HDAC1 inhibitory activity, which was comparable to or superior to SAHA.
Example 22: antitumor cell proliferation Activity of Compounds of the present invention
In this example, SAHA was used as a positive control, and the anti-proliferative activity of the compound of the present invention and SAHA on lung cancer cell line A549 and colon cancer cell line HCT116 was evaluated by CCK-8 method. Other compounds of the present invention have similar beneficial effects to those listed below, but this should not be understood as the only beneficial effects of the compounds of the present invention.
The test procedure for the anti-tumor cell proliferation activity was: digesting and collecting tumor cells, inoculating the cells in a 96-well culture plate at a certain density, and placing the plate in an incubator (37 ℃, 5% CO)2) Overnight. After the compound is applied for 72h, the culture medium is discarded, and the cells are washed gently with PBS 3 times. Subsequently, a certain volume of medium and CCK-8 were added to each well of the plate, and the incubation was continued for a certain period of time. Finally, a multifunctional microplate reader is adopted to measure the OD value of absorbance under the wavelength of 570nm, and the inhibition rate, GI is calculated50Values were fitted by GraphPad Prism 5 software.
Table 2: antitumor cell proliferation activity of the compound
In the above table: "+ ++" represents < 0.1. mu.M; "+ + + +" represents 0.1-1.0. mu.M; "+ +" represents 1.0-10. mu.M; "+" represents 10-50. mu.M.
As can be seen from the data in Table 2, all the compounds listed exhibit significant anti-tumor cell proliferation activity, which is comparable to or superior to SAHA.
Example 23: HDAC6 Selectivity or class I HDACs Selectivity of Compounds of the invention
The literature indicates that the selectivity of the compounds for inhibiting HDAC isoforms can be reflected by the activity of inhibiting HDAC1, 2, 3, 6,8, 10, 11 enzymes (Yu CW, et al Quinazolin-2,4-dione-Based Hydroxamic Acids as selective Histone deacylase-6 Inhibitors for Treatment of Non-Small cell Lung cancer. J Med Chem,2019,62)
Test methods for inhibitory activity of compounds against HDAC 6and other HDAC isomerases the catalytic reaction system substrates were only replaced when the corresponding enzyme inhibitory activity was tested, in reference to the test method for HDAC1 inhibitory activity.
The selectivity of the partial compounds of the present invention for HDAC6 or HDAC1/2/3 is further illustrated by the inhibitory activity data of HDAC1, 2, 3, 6,8, 10, 11. It is not to be understood that the present invention is only the following compounds which have selectivity for HDAC6 or HDAC 1/2/3.
Table 3: inhibitory Activity of Compounds on HDAC1, 2, 3, 6,8, 10, 11
In the above table: "+ ++" represents 0-10 nM; "+ + + +" represents 10-100 nM; "+ +" represents 100 and 1000 nM; "+" represents 1000-10000 nM.
As shown in table 3, compound 3 according to formula (I) and compounds 12, 19, and 20 according to formula (III) have significant inhibitory activity against HDAC6, but relatively weak inhibitory activity against HDACs 1,2, 3, 8, 10, and 11, and are selective HDAC6 inhibitors. The compound 21 has remarkable inhibiting activity on HDAC1, 2 and 3, and relatively weaker inhibiting activity on HDAC6, 8, 10 and 11, so the compound is a selective HDAC1/2/3 inhibitor. Compared with the broad-spectrum HDACs inhibitor SAHA, the compounds 3, 12, 19, 20 and 21 of the present invention, while significantly inhibiting the corresponding HDAC subtype, are beneficial to reduce the toxicity of SAHA to all HDAC subtype inhibition.
In conclusion, the compound prepared by the invention has good application prospect.
Claims (8)
1. A class of HDAC inhibitors characterized by: the inhibitor is a bifendate derivative shown in the following general formulas (I) to (IV) and a pharmaceutically acceptable salt or a deuteron thereof:
in the above formula, W is (CH)2)n1Or at least 1R1Substituted C6-14 aryl, C5-14 heteroaryl, C7-12 aralkyl, C6-12 heteroaralkyl;
x is at least 1R2Substituted C6-14 aryl, C5-14 heteroaryl, C7-12 aralkyl, C6-12 heteroaralkyl orWherein Y is at least 1R3Substituted C6-14 aryl, C5-14 heteroaryl;
z is at least 1R4Substituted C6-14 aryl, C5-14 heteroaryl;
n1=1-9;R1、R2、R3、R4each independently selected from hydrogen, halogen, hydroxy, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon; r5Is hydrogen, C1-6 alkyl orn2=1-4。
2. The class of HDAC inhibitors according to claim 1, wherein: the bifendate derivative is selected from the following compounds:
3. the class of HDAC inhibitors according to claim 1, wherein: the HDAC inhibitor is a selective HDAC 6inhibitor, the selective HDAC 6inhibitor is a bifendate derivative shown as general formulas (I) and (III) and a pharmaceutically acceptable salt or deuteron thereof,
wherein in the general formula (I), W is at least 1R1Substituted C6-14 aryl, C5-14 heteroaryl;
in the general formula (III), X is at least 1R2Substituted C6-14 aryl, C5-14 heteroaryl orAnd Y is at least 1R3Substituted C6-14 aryl, C5-14 heteroaryl; r1、R2、R3Each independently selected from hydrogen, halogen, hydroxy, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon; r5Is hydrogen, C1-6 alkyl orn2=1-4。
4. The class of HDAC inhibitors according to claim 1, wherein: the HDAC inhibitor is a selective HDAC1/2/3 inhibitor, the HDAC1/2/3 inhibitor is a biphenyl diester derivative shown as a general formula (IV) and a pharmaceutically acceptable salt or a deuteron thereof,
wherein in the general formula (IV), Z is at least substituted by 1R4Substituted C6-14 aryl, C5-14 heteroaryl; r4Independently selected from hydrogen, halogen, hydroxyl, cyano, carbamoyl, C1-6 alkyl, C1-6 alkoxy, C2-6 unsaturated aliphatic hydrocarbon.
5. An HDAC inhibitor composition characterized by: comprising an HDAC inhibitor as claimed in any one of claims 1to 4 together with at least one pharmaceutically acceptable carrier or excipient.
6. The HDAC inhibitor composition of claim 5, wherein: further comprising at least one other therapeutic agent; the dosage form of the HDAC inhibitor composition is any clinically or pharmaceutically acceptable dosage form.
7. The use of an HDAC class inhibitor as claimed in any of claims 1-4 wherein: the HDAC inhibitor is applied to the preparation of anti-tumor, autoimmune disease, inflammation or Alzheimer disease drugs.
8. Use of a composition according to claim 5 or 6, characterized in that: the composition is applied to the preparation of anti-tumor, autoimmune disease, inflammation or Alzheimer's disease drugs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910992789.6A CN110627801B (en) | 2019-10-17 | 2019-10-17 | HDAC inhibitor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910992789.6A CN110627801B (en) | 2019-10-17 | 2019-10-17 | HDAC inhibitor and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110627801A true CN110627801A (en) | 2019-12-31 |
CN110627801B CN110627801B (en) | 2021-07-02 |
Family
ID=68976701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910992789.6A Active CN110627801B (en) | 2019-10-17 | 2019-10-17 | HDAC inhibitor and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110627801B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848629A (en) * | 2020-07-15 | 2020-10-30 | 安徽中医药大学 | mTOR/HDAC dual inhibitor and application thereof |
CN113754627A (en) * | 2021-09-03 | 2021-12-07 | 西北师范大学白银师科创新研究院 | Preparation method of biphenylol acid |
CN114805375A (en) * | 2022-04-12 | 2022-07-29 | 徐州医科大学 | N-phenyl alkoxy dibenzoazepine compound, preparation method and medical application thereof |
WO2022203429A1 (en) * | 2021-03-26 | 2022-09-29 | Chong Kun Dang Pharmaceutical Corp. | Composition for preventing or treating multiple sclerosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04202153A (en) * | 1990-11-29 | 1992-07-22 | Tokyo Tanabe Co Ltd | New tricyclic composition having treating action on hepatic disease |
CN102532150A (en) * | 2012-02-27 | 2012-07-04 | 中国药科大学 | Alkoxyl dibenzoazepine compound, and preparation method and medical application thereof |
CN107266461A (en) * | 2017-06-20 | 2017-10-20 | 徐州医科大学 | A kind of alkoxy dibenzazepines class compound, its preparation method and medical usage |
-
2019
- 2019-10-17 CN CN201910992789.6A patent/CN110627801B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04202153A (en) * | 1990-11-29 | 1992-07-22 | Tokyo Tanabe Co Ltd | New tricyclic composition having treating action on hepatic disease |
CN102532150A (en) * | 2012-02-27 | 2012-07-04 | 中国药科大学 | Alkoxyl dibenzoazepine compound, and preparation method and medical application thereof |
CN107266461A (en) * | 2017-06-20 | 2017-10-20 | 徐州医科大学 | A kind of alkoxy dibenzazepines class compound, its preparation method and medical usage |
Non-Patent Citations (1)
Title |
---|
XIAOKE GU 等: "Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848629A (en) * | 2020-07-15 | 2020-10-30 | 安徽中医药大学 | mTOR/HDAC dual inhibitor and application thereof |
WO2022203429A1 (en) * | 2021-03-26 | 2022-09-29 | Chong Kun Dang Pharmaceutical Corp. | Composition for preventing or treating multiple sclerosis |
CN113754627A (en) * | 2021-09-03 | 2021-12-07 | 西北师范大学白银师科创新研究院 | Preparation method of biphenylol acid |
CN114805375A (en) * | 2022-04-12 | 2022-07-29 | 徐州医科大学 | N-phenyl alkoxy dibenzoazepine compound, preparation method and medical application thereof |
CN114805375B (en) * | 2022-04-12 | 2023-07-25 | 徐州医科大学 | N-phenylalkoxy dibenzoazepine compound, preparation method and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110627801B (en) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110627801B (en) | HDAC inhibitor and application thereof | |
CN107922425B (en) | Methods of preparing PARP inhibitors, crystalline forms and uses thereof | |
CN108699081B (en) | A kind of macrocyclic compound and the composition comprising the compound | |
CN112939965B (en) | Compound for simultaneously inducing degradation of EGFR (epidermal growth factor receptor) and PARP (para-amyloid peptide) proteins as well as preparation method and application thereof | |
WO2017088723A1 (en) | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof | |
CN114072413B (en) | c-Myc protein inhibitor and preparation method and application thereof | |
Wei et al. | Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors | |
US20110275671A1 (en) | Dihydroindolinone derivatives | |
CN103833756A (en) | Pyridazinone compound as well as preparation method and application thereof | |
CN112174940A (en) | 3- (6, 7-bis (2-methoxyethoxy) -quinazoline-4-amido) phenyl-1H-triazole derivative | |
EP2233467B1 (en) | Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof | |
CN115368306B (en) | HDAC inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | |
CN108530337B (en) | Indoleamide compound capable of selectively inhibiting gastric cancer cells | |
CN114437113B (en) | Thiazolopyridine cyclotriazole compound, and preparation method and application thereof | |
CN112500412B (en) | Penamine A alkaloid structure simplification compound and application thereof | |
CN111848629B (en) | mTOR/HDAC dual inhibitor and application thereof | |
CN107056771A (en) | Bromodomain albumen bivalent inhibitors and its preparation method and application | |
EP3677581A1 (en) | Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof | |
CN102485735B (en) | 6-fructosamine-4-arylamidoquinazoline derivative and purpose thereof | |
CN108129468B (en) | Aspirin derivatives and preparation method and application thereof | |
CN114933599B (en) | Double beta-carboline compound and medicinal salt, preparation method and application thereof | |
CN115057850B (en) | Aloe-emodin derivative and preparation method and application thereof | |
KR100874209B1 (en) | 3,10-dihydro-1h-[1,4]diazepino[5,6-b]indol-2-one derivatives and pharmaceutically acceptable salt thereof, process for preparation thereof and use thereof | |
CN102690269A (en) | Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof | |
CN117430565A (en) | HDAC8 inhibitor and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210608 Address after: 230012 No.1 Qianjiang Road, Xinzhan District, Hefei City, Anhui Province Applicant after: ANHUI University OF CHINESE MEDICINE Address before: 230012 No.1 Qianjiang Road, Xinzhan District, Hefei City, Anhui Province Applicant before: ANHUI University OF CHINESE MEDICINE Applicant before: HEFEI YUANZHI PHARMACEUTICAL R & D Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |